Fusion Pharmaceuticals Inc. – NASDAQ:FUSN
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Fusion Pharmaceuticals stock price monthly change
+0.47%
month
Fusion Pharmaceuticals stock price quarterly change
+87.07%
quarter
Fusion Pharmaceuticals stock price yearly change
+409.46%
year
Fusion Pharmaceuticals key metrics
Market Cap | 1.83B |
Enterprise value | 170.94M |
P/E | -2.05 |
EV/Sales | 117.00 |
EV/EBITDA | -1.96 |
Price/Sales | 119.47 |
Price/Book | 1.07 |
PEG ratio | 0.38 |
EPS | -1.42 |
Revenue | N/A |
EBITDA | -106.60M |
Income | -104.27M |
Revenue Q/Q | -100% |
Revenue Y/Y | 3846.46% |
Profit margin | -5996.71% |
Oper. margin | -6025.6% |
Gross margin | 0% |
EBIT margin | -6025.6% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFusion Pharmaceuticals stock price history
Fusion Pharmaceuticals stock forecast
Fusion Pharmaceuticals financial statements
| Jun 2023 | 34K | -25.17M | -74044.12% |
|---|---|---|---|
| Sep 2023 | 2.00M | -17.25M | -860.02% |
| Dec 2023 | 33.63M | -28.17M | -83.78% |
| Mar 2024 | 0 | -33.67M |
| Sep 2025 | 40.21M | -29.84M | -74.21% |
|---|---|---|---|
| Oct 2025 | 0 | -36.69M | |
| Dec 2025 | 6.51M | -33.14M | -508.38% |
| Dec 2025 | 0 | -37.41M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -0.4 | -0.25 |
|---|---|---|
| 2024-03-04 | -0.34 | -0.39 |
| Jun 2023 | 268286000 | 65.32M | 24.35% |
|---|---|---|---|
| Sep 2023 | 253377000 | 64.90M | 25.62% |
| Dec 2023 | 285836000 | 63.35M | 22.17% |
| Mar 2024 | 323814000 | 81.98M | 25.32% |
| Jun 2023 | -19.58M | -26.31M | 24.30M |
|---|---|---|---|
| Sep 2023 | -18.83M | 13.32M | 328K |
| Dec 2023 | -16.93M | -4.69M | 56.21M |
| Mar 2024 | -27.30M | -70.37M | 64.01M |
Fusion Pharmaceuticals alternative data
| Aug 2023 | 106 |
|---|---|
| Sep 2023 | 101 |
| Oct 2023 | 101 |
| Nov 2023 | 101 |
| Dec 2023 | 101 |
| Jan 2024 | 101 |
| Feb 2024 | 101 |
| Mar 2024 | 101 |
| Apr 2024 | 101 |
| May 2024 | 101 |
| Jun 2024 | 101 |
| Jul 2024 | 101 |
Fusion Pharmaceuticals other data
50.66%
-14.29%
of FUSN is owned by hedge funds
17
-11
22.16M
-6.20M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2022 | 0 | 99551 |
| Mar 2022 | 0 | 65423 |
| Apr 2022 | 0 | 48813 |
| Aug 2022 | 44400 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GANNON STEVEN director | Common Stock | 44,400 | $2.03 | $90,132 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 4,511 | $6.03 | $27,201 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 2,147 | $6.07 | $13,032 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 2,036 | $6.03 | $12,277 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 922 | $6.01 | $5,541 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 367 | $6.02 | $2,209 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 11,994 | $6.41 | $76,882 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 18,255 | $7.1 | $129,611 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 2,600 | $7.37 | $19,162 | ||
Sale | VALLIANT JOHN director, officer.. | Common Stock | 826 | $7.52 | $6,212 |
| Patent |
|---|
Application Filling date: 29 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 3 Dec 2019 Issue date: 24 Mar 2022 |
Application Filling date: 8 Jan 2021 Issue date: 23 Dec 2021 |
Application Filling date: 2 Jun 2021 Issue date: 23 Sep 2021 |
Application Filling date: 2 Jun 2021 Issue date: 23 Sep 2021 |
Application Filling date: 27 Apr 2020 Issue date: 1 Oct 2020 |
| Insider | Compensation |
|---|---|
| Dr. John F. Valliant (1970) Founder, Chief Executive Officer & Director | $845,500 |
Mr. John J. Crowley CPA (1974) Chief Financial Officer | $646,430 |
| Dr. Eric Burak Ph.D. (1965) Chief Technology Officer | $600,780 |
| Dr. James J. O'Leary (1965) Chief Medical Officer | $537,640 |
-
When is Fusion Pharmaceuticals's next earnings date?
Unfortunately, Fusion Pharmaceuticals's (FUSN) next earnings date is currently unknown.
-
Does Fusion Pharmaceuticals pay dividends?
No, Fusion Pharmaceuticals does not pay dividends.
-
How much money does Fusion Pharmaceuticals make?
Fusion Pharmaceuticals has a market capitalization of 1.83B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 41.55% to 2.07M US dollars. Fusion Pharmaceuticals made a loss 94.9M US dollars in net income (profit) last year or -$0.39 on an earnings per share basis.
-
What is Fusion Pharmaceuticals's stock symbol?
Fusion Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "FUSN".
-
What is Fusion Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Fusion Pharmaceuticals?
Shares of Fusion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Fusion Pharmaceuticals's key executives?
Fusion Pharmaceuticals's management team includes the following people:
- Dr. John F. Valliant Founder, Chief Executive Officer & Director(age: 55, pay: $845,500)
- Mr. John J. Crowley CPA Chief Financial Officer(age: 51, pay: $646,430)
- Dr. Eric Burak Ph.D. Chief Technology Officer(age: 60, pay: $600,780)
- Dr. James J. O'Leary Chief Medical Officer(age: 60, pay: $537,640)
-
Is Fusion Pharmaceuticals founder-led company?
Yes, Fusion Pharmaceuticals is a company led by its founder Dr. John F. Valliant.
-
How many employees does Fusion Pharmaceuticals have?
As Jul 2024, Fusion Pharmaceuticals employs 101 workers.
-
When Fusion Pharmaceuticals went public?
Fusion Pharmaceuticals Inc. is publicly traded company for more then 5 years since IPO on 26 Jun 2020.
-
What is Fusion Pharmaceuticals's official website?
The official website for Fusion Pharmaceuticals is fusionpharma.com.
-
Where are Fusion Pharmaceuticals's headquarters?
Fusion Pharmaceuticals is headquartered at 270 Longwood Road South, Hamilton, ON.
-
How can i contact Fusion Pharmaceuticals?
Fusion Pharmaceuticals's mailing address is 270 Longwood Road South, Hamilton, ON and company can be reached via phone at 289 799 0891.
Fusion Pharmaceuticals company profile:
Fusion Pharmaceuticals Inc.
fusionpharma.comExchange:
NASDAQ
Full time employees:
101
Industry:
Biotechnology
Sector:
Healthcare
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
270 Longwood Road South
Hamilton, ON L8P 0A6
Hamilton, ON L8P 0A6
CIK: 0001805890
ISIN: CA36118A1003
CUSIP: 36118A100
